Evobrutinib

DB15170InvestigationalSmall molecule

Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₂₅H₂₇N₅O₂ · 429.524 g/mol (avg)
Code names: MSC-2364447

Resolves to

Compound

Structure

InChIKeyQUIWHXQETADMGN-UHFFFAOYSA-NSMILESNC1=NC=NC(NCC2CCN(CC2)C(=O)C=C)=C1C1=CC=C(OC2=CC=CC=C2)C=C1

Targets

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Evobrutinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.